stock-detail (CYCC)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

4/23/2017 12:17 pm

4/23/2017 12:17 pm

4/23/2017 12:17 pm

4/23/2017 12:17 pm

4/23/2017 12:17 pm

4/11/2017 06:17 am

4/11/2017 06:17 am

4/11/2017 06:17 am

4/11/2017 06:17 am

4/11/2017 06:17 am

4/7/2017 06:17 am

4/7/2017 06:17 am

4/7/2017 06:17 am

4/7/2017 06:17 am

Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Elicits Marked Antineoplastic Effects in Lung Cancer by Engaging Anti-Metastatic Pathways

4/2/2017 05:00 pm

[GlobeNewswire] - BERKELEY HEIGHTS, N.J., April 02, 2017-- Cyclacel Pharmaceuticals, Inc., today announced the presentation by independent investigators of preclinical data demonstrating therapeutic potential of CYC065, ...

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results

3/28/2017 08:00 pm

[GlobeNewswire] - BERKELEY HEIGHTS, N.J., March 28, 2017-- Cyclacel Pharmaceuticals, Inc. a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer ...

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2016 Financial Results

3/21/2017 11:00 am

[GlobeNewswire] - BERKELEY HEIGHTS, N.J., March 21, 2017-- Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of ...

Cyclacel’s CDK Inhibitor CYC065 Causes Anaphase Catastrophe, a Novel Cancer-Specific Mechanism of Action, in Research Published in JNCI

3/7/2017 12:00 pm

[GlobeNewswire] - BERKELEY HEIGHTS, N.J., March 07, 2017-- Cyclacel Pharmaceuticals, Inc., today announced the publication of a peer-reviewed journal article featuring the company’ s cyclin dependent kinase 2/ 9 inhibitors. ...